• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

405.41 -2.42 (-0.59%)
Streaming Delayed Price Updated: 10:17 AM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
69 70 Next >
News headline image
Is Amgen Stock a Buy Now? ↗
February 01, 2024
The biotech has an excellent track record, but that isn't enough to make its shares attractive. 
Via The Motley Fool
News headline image
IBM, Verizon, Merck stocks lead Dow to new highs
January 31, 2024
The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance 
Via MarketBeat
Topics Stocks
News headline image
Amgen Options Trading: A Deep Dive into Market Sentiment ↗
January 30, 2024
 
Via Benzinga
News headline image
Expert Outlook: Amgen Through The Eyes Of 11 Analysts ↗
January 29, 2024
 
Via Benzinga
News headline image
Is Amgen a Good Dividend Stock to Buy Right Now? ↗
January 29, 2024
Its diverse product mix and strong fundamentals make a decent case. 
Via The Motley Fool
News headline image
P/E Ratio Insights for Amgen ↗
January 26, 2024
 
Via Benzinga
News headline image
Amgen Options Trading: A Deep Dive into Market Sentiment ↗
January 17, 2024
 
Via Benzinga
News headline image
Why NASDAQ:AMGN is a Top Pick for Dividend Investors. ↗
January 12, 2024
Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN). 
Via Chartmill
News headline image
How Is The Market Feeling About Amgen? ↗
January 10, 2024
 
Via Benzinga
News headline image
Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock. ↗
January 27, 2024
Its new approach to treating cancer is more than just a nibble around the edges. 
Via The Motley Fool
News headline image
Should You Buy the Dogs of the Dow in 2024? ↗
January 27, 2024
The popular dividend-investing strategy has been around for years. Is it right for you? 
Via The Motley Fool
Topics Stocks
News headline image
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
News headline image
ABBV: This Top Biotech Just Went On A Buying Spree ↗
January 25, 2024
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
News headline image
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs ↗
January 25, 2024
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments. 
Via InvestorPlace
News headline image
What's Going On Johnson & Johnson Stock Today? ↗
January 24, 2024
JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch. 
Via Benzinga
Topics Earnings
News headline image
This 1 Bullish Move by Merck Could Drive Growth for Years to Come ↗
January 23, 2024
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually. 
Via The Motley Fool
News headline image
5 Magnificent Dividend Growth Stocks to Buy and Hold Forever ↗
January 23, 2024
These dividend growers ought to shine in 2024 and beyond. 
Via The Motley Fool
News headline image
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning ↗
January 19, 2024
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups. 
Via Benzinga
News headline image
Dividend Income Update December 2023 ↗
January 17, 2024
The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. 
Via Talk Markets
News headline image
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units ↗
January 16, 2024
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
Via Benzinga
Topics ETFs
News headline image
Stocks Struggle As U.S. Dollar Sees Safety Bid ↗
January 16, 2024
Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well. 
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
January 15, 2024
 
Via Benzinga
News headline image
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗
January 15, 2024
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
News headline image
Why Vera Therapeutics Stock Soared by 22% This Week ↗
January 12, 2024
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
News headline image
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
News headline image
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗
January 11, 2024
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
News headline image
Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains ↗
January 10, 2024
Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed. 
Via InvestorPlace
Topics Stocks
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
Via Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap